VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

The ongoing phase 3 VERITAC-2 trial is comparing the efficacy and safety of ARV-471 to fulvestrant in approximately 560 patients with ER+ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor and endocrine therapy. Progression-free survival is the primary endpoint; secondary endpoints include overall survival, antitumor activity, safety, and quality of life assessments.